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Background/aim: Currently there is not an effective antiviral treatment for COVID-19, but a large number of drugs have been evaluated
since the beginning of the pandemic, and many of them have been used for the treatment of COVID-19 despite the preliminary or
conflicting results of the clinical trials. We aimed to review and summarize all of the current knowledge on the antivirals for COVID-19.
Results: There are 2 main drug groups for SARS-CoV-2: agents that target proteins or RNA of the virus or interfere with proteins
or biological processes in the host that support the virus. The main drug groups include inhibitors of viral entry into the human cell
(convalescent plasma, monoclonal antibodies, nanobodies, mini proteins, human soluble ACE-2, camostat, dutasteride, proxalutamide,
bromhexin, hydroxychloroquine, umifenovir nitazoxanid, niclosamide, lactoferrin), inhibitors of viral proteases (lopinavir/ritonavir,
PF-07321332, PF-07304814, GC376), inhibitors of viral RNA (remdesivir, favipiravir, molnupiravir, AT-527, merimepodib, PTC299),
inhibitors of host proteins supporting virus (plitidepsin, fluvoxamine, ivermectin), and agents supporting host natural immunity
(Interferons).
Conclusion: When taking into account the results of all the available laboratory and clinical trials on the subject, monoclonal antibodies
seem to be the most effective treatment for COVID-19 at the moment, and high-titer convalescent plasma also could be effective when
administered during the early phase of the disease. As lopinavir/ritonavir, hydroxychloroquine, merimepodib, and umifenovir were
found to be ineffective in RCTs, they should not be used. Additional studies are needed to define the role of remdesivir, favipiravir,
interferons, ivermectin, dutasteride, proxulutamide, fluvoxamine, bromhexine, nitazoxanide, and niclosamid in the treatment of
COVID-19. Finally, the results of phase trials are waited to learn whether or not the newer agents such as molnupiravir, PF-07321332,
PF-07304814, plitidepsin and AT-527 are effective in the treatment of COVID-19.
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1. Introduction
Although 18 months have been passed since the beginning
of COVID-19 pandemic, an effective antiviral treatment
still has yet to be found. The big achievement of finding
highly effective vaccines was not repeated in the case of
antiviral treatment. It is obvious that the success of mRNA
vaccines mainly relies on nearly 30 years’ hard work of
numerous scientists [1]. Despite warnings of scientists
and policymakers in the field to be prepared for the next
pandemic and develop and stockpile drugs that target
a wide range of viral pathogens since the 2003 SARS
epidemic, pharmaceutical companies, and researchers
ignored the warns.
After the SARS outbreak was taken under control, all
of the antiviral studies terminated. If those researches had

been completed, we would have had something in the
stockpile for the treatment of COVID-19 now [2]. But with
the help of new huge investments, it is hoped that effective
antivirals could be found by the end of 20211.
Early efforts to identify effective antiviral for COVID-19
have mainly focused on drug repurposing screens to
identify drugs with antiviral activity against SARS-CoV-2
in cell cultures. But the cell types in the cultures were
not always appropriate to predict the physiological and
pathological events in the human cells. For example, a
deeper understanding of the viral entry pathways revealed
that agents affect only endosomal pathways but not
fusional ones, for example hydroxychloroquine would be
ineffective for the treatment of COVID-19. In addition to
understanding the viral entry pathways of SARS-CoV-2 to

Economic Times. Anti-Covid tablets by 2021 end? Fauci says US to spend $3.2bn for COVID antiviral pills. Website https://economictimes.indiatimes.
com/news/international/world-news/anti-covid-tablets-by-2021-end-fauci-says-us-to-spend-3-2bn-for-covid-antiviral-pills/videoshow/83627082.cms
[accessed 19 June 2021].
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different cell types, consideration also should be given to
the degree of nucleotide prodrug activation observed in
the in vitro screening cell types [3].
The majority of COVID-19 patients will recover
without any therapy. However, initiating therapy after
patients are severely ill could not be effective as it is known
that antiviral therapy is mostly useful when initiated
earlier during the course of the disease. It is logical to start
antiviral treatment immediately for COVID-19 patients
especially in whom at high risk of severe disease [4].
In this review, we aimed to summarize the current
knowledge on the antiviral treatment of COVID-19.
Investigated antivirals for SARS-CoV-2 can be divided
into 2 groups: agents that target proteins or RNA of
the virus; S protein, viral proteases (nonstructural
protein (NSP)-3 and NSP-5), viral RNA dependent
RNA polymerase (NSP-12) are the main viral targets.
Agents that target host proteins are host proteases, which
can help entry of the virus into the cell (Angiotensin
converting enzyme-2 (ACE-2), transmembrane protease
serine 2 (TMPRSS2), furin, catepsin-L), heparin
sulfate proteogylicans (HSPGs) that promote the
viral cell attachment, eukaryotic translation proteins
(translation initiation factor 4A (eIF4A), translation
elongation factor 1a (eEF1A), endosplasmic reticulum
chaperon protein (S1R, etc.)), transcription machineries
(inosine monophospate dehydrogenase, dihydroorarate

dehydrogenase, etc.), and host nuclear importer of viral
proteins ( IMPα/β1) [2] (Figure).
Those are the drug groups that either laboratory or
clinical studies are going to find as an effective antiviral
against SARS-CoV-2:
1) Inhibitors of viral entry into the human cell:
a.
Inhibitors of S protein: Convalescent plasma,
monoclonal antibodies, nano bodies, miniproteins, human
soluble ACE-2.
b. Inhibitors of fusional entry:
i.
TMPRSS2 inhibitors (camostat, nafamostat,
gabexat, dutasteride, proxalutamide, bromhexin,
nitazoxanid, niclosamide),
c.
Inhibitors of endosomal entry: Catepsin L
inhibitors (teicoplanin, SSAA09E1, K1777); furin
inhibitors (dec-RVKR-cmk), NIP1 inhibitors (EG00229),
hydroxychloroquine,
nitazoxanide,
niclozamide,
umifenovir,
d. HSPG inhibitors (lactoferrin).
2) Inhibitors of viral proteases: inhibitors of viral
main protease (Mpro) (lopinavir/ritonavir, PF-07321332,
PF-07304814, GC376); inhibitors of viral papain-like
protease (PL pro).
3) Inhibitors of viral RNA: inhibitors of RNA
dependent RNA polymerase (RdRp) (remdesivir,
favipiravir, molnupiravir, AT-527), inhibitors of host
proteins supporting viral RNA synthesis (inhibitor of
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inosine monophospate dehydrogenase (merimepodib),
inhibitor of dihydroorarate dehydrogenase (PTC299).
4) Inhibitors of host proteins supporting viral
protein synthesis: inhibitors of eEF1A (plitidepsin); S1R
agonists (fluvoxamin).
5) Inhibitors of viral immunomodulation: Inhibitors
of host importin α/β (ivermectin).
6) Agents supporting host natural immunity:
interferons.
2. Inhibitors of virus entry into the human cell
The attachment and entry of SARS-COV-2 into the human
cells is the first step in the COVID-19 pathogenesis.
SARS-CoV-2 enters the host cells by binding its spike (S)
protein to the cellular ACE2. In recent studies, cell surface
HSPGs were reported to be a necessary cofactor for ACE2
mediated SARS-CoV-2 entry [5,6]. The virion enters
through endocytosis and/or direct fusion of cell and viral
membranes. The SARS-CoV-2 spike (S) glycoprotein is a
transmembrane homotrimer. The S protein is cleaved by
various cellular proteases (e.g., TMPRSS2, furin, catepsin
L, etc) into two subunits, S1 and S2, which is named as
priming process, and S2 functions as fusion peptide [7].
As the entry of SARS-CoV-2 into host cells is critical for
infection, it becomes an extremely attractive therapeutic
interventional step [8].
Viral entry inhibitors target either S protein (convalescent
plasma, monoclonal antibodies, nanobodies, miniproteins
and soluble human ACE-2) or host ACE-2 receptor, or
host proteins including proteases and HSPGs that help
viral entry (Figure).
2.1. Inhibitors of S protein
2.1.1. Convalescent plasma
Given the lack of effective treatment of COVID-19,
classical interventions like convalescent plasma (CP) have
remerged as treatment options. CP is a strategy of passive
immunization and has been used in prevention and
treatment of so many infectious diseases since early 20th
century. The CP is obtained using apheresis in survivors
with prior COVID-19 in whom neutralizan antibodies
(NAbs) against the SARS-CoV-2 are developed. The
efficacy of this therapy has been shown to be associated
with the concentration of NAbs directed to the receptorbinding domain (S1-RBD) and N-terminal domains (S1NTD) of S protein. Those NAbs inhibit the entry of SARSCoV-2 into the host cell and limit viral amplification [9].
Several retrospective observational studies in 2020
suggested a beneficial role of CP for patients hospitalized
with severe COVID-19, and these initial reports led to
Emergency Use Authorization (EUA) of CP all over the

World [10, 11]. But following randomized controlled trials
(RCT)s did not confirm the positive findings of those
preliminary observational studies [12].
In a metaanalysis of randomized clinical trials (1060
patients) with COVID-19 treated with CP versus control,
it was concluded that treatment with CP compared with
placebo or standard of care was not significantly associated
with a decrease in all-cause mortality or with any benefit
for other clinical outcomes [13].
But in a recent randomized, double-blinded, placebocontrolled trial of 160 older adult patients within 72
h after the onset of mild COVID-19 symptoms, early
administration of high-titer CP against SARS-CoV-2
reduced the progression of COVID-19 significantly by a
relative risk of 0.52 (95% confidence interval [CI], 0.29 to
0.94; p = 0.03) [14].
Also, in a retrospective study of 3082 patients
hospitalized with COVID-19, transfusion of plasma
with higher anti–SARS-CoV-2 IgG antibody levels were
associated with a lower risk of death than transfusion of
plasma with lower antibody levels with a relative risk of
0.66 (95% CI, 0.48 to 0.91) among patients who had not
received mechanical ventilation before transfusion [15].
These studies suggested that CP against COVID-19
work better when administered early (first 72 h of
symptoms, etc.) in the course of the illness and a dosedependent IgG effect in CP infusions. Taking into account
of extremely higher NABs titers among mRNA immunized
persons [16], it will be quite possible that CP of those
people could contribute to building a cheap and effective
therapeutic option in the future with the help of additional
RCTs.
In conclusion, high-titer CP given within 72 h of
symptom onset to high-risk adult outpatients (including
≥65 years, obesity, with comorbidities diabetes mellitus,
hypertension, chronic obstructive lung disease,
cardiovascular disease, chronic renal failure) with mild
illness seems to have efficacy in reducing the risk of
progression to severe disease. However, high-titer CP
therapy is still investigational and should be administered
in the context of a clinical trial if possible.
2.1.2. Monoclonal antibodies
In the case of SARS-CoV-2, S glycoprotein is the target of
neutralizing antibodies [17].
In RCTs, bamlanivimab, bamlanivimab-etesevimab,
casirivimab-imdevimab, and sotrovimab (VIR-7831)
reduced the rate of hospitalization plus dead (visit to an
emergency department for bamlanivimab) by 61%, 87%,
72%, and 86%, respectively [18,19]2,3 among outpatients.
In the global phase 2/3 trial of regdenvimab, it was reduced

Investor/Lilly. Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19 Website https://
investor.lilly.com/news-releases/news-release-details/lillys-bamlanivimab-and-etesevimab-together-reduced [accessed 16 June 2021].
2

Gupta A, Gonzalez-Rojas Y, Juarez E, Casal MC, Moya J, at al. Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab. medRxiv
preprint 2021; doi: https://doi.org/10.1101/2021.05.27.21257096[accessed 16 June 2021].
3
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the progression rate to severe COVID-19 by 54% for
patients with mild-to-moderate symptoms [17]. But, in an
interim analysis of an RCT, bamlivimab was found to be
ineffective among hospitalized patients with COVID-19,
and the study was stopped early for futility [20].
In the RECOVERY’s monoclonal antibody
combination of casirivimab and imdevimab (REGENCOV) trial, 9785 patients hospitalised with COVID-19
were randomly given usual care plus REGEN-COV or
usual care alone, including 3153 (32%) seronegative and
5272 (54%) seropositive patients. They found that, in
patients hospitalised with COVID-19, the monoclonal
antibody REGEN-COV combination reduced 28-day
mortality among patients who were seronegative at
baseline (rate ratio 0.80; 95% CI 0.70–0.91; 43 p = 0·0010)4.
Several mAbs received EUAs all over the world
including, USA, Europe, South Korea, and India. As no
dose response was observed in most of those clinical
trials, it was thought that mAbs likely overdosed. Lower
doses could be administered by more easy routes such
as intramuscular or subcutaneous, and the shift to these
different routes is underway and will possibly contribute to
facilitated and larger access to these mAb [17]. In a RCT,
subcutaneous (SC) REGEN-COV 1200mg was compared
with placebo in SARS-CoV-2-positive cases. REGENCOV 1200mg SC significantly prevented progression from
asymptomatic to symptomatic disease compared with
placebo (31.5% relative risk reduction; 29/100 (29.0%)
versus 44/104 (42.3%), respectively; p = 0.0380)5.
After getting encouraging results from the RCTs,
COVID-19
treatment
guidelines
recommended
bamlanivimab/etesevimab or casirivimab/imdevimab for
ambulatory patients with mild to moderate COVID-19
(not requiring supplemental oxygen) and at high risk
for progression to severe disease. These risk factors
include older age (≥65 years), obesity, pregnancy, chronic
kidney disease, diabetes mellitus, immunosuppression,
cardiovascular diseases, chronic lung disease, neurological
development disorders, sickle cell disease, and other
medically complex conditions6.
As evidence from CP treatment show that benefit is
maximized with early administration, mABs treatment
should be given as soon as possible after the diagnosis and
within seven days of symptom onset.
All mAbs authorized or in development are directed
to the RBD, which interacts with the target receptor ACE2

and, as a result, could be susceptible to mutation of viral
RBD. Immune-evading SARS-CoV-2 variants have been
emerging from the beginning of the pandemic and may
potentially continue to emerge with implications for mAb
therapeutics. As a result, it is recommended that local
variant susceptibility should be considered in the choice
of the most appropriate neutralizing antibody therapy. In
April 2021, Eli Lilly requested revocation of the EUA for
bamlanivimab, because of an increase in variants resistant
to bamlanivimab monotherapy. In any case, emergence of
resistance to mAbs should be monitored for all variants
[17]. Both high-titer CP and mAbs may be more important
and efficient for subgroup of immunocompromised
patients with B-cell depletion.
2.1.3. Nanobodies
The camelid family, which includes lamas and camels,
produces only heavy chain antibodies that are composed
of two heavy chains. Nbs have the ability to function as
an independent antigen-binding domain with similar
affinity as a conventional IgG. Nbs have been successfully
humanized without significant alteration of biophysical
properties. Caplacizumab, the first-in-class nanobody
was approved recently for the treatment of thrombotic
thrombocytopenic purpura [21], which boosters the
therapeutic potential of Nb derivatives. Nbs that bind to
the SARS-CoV-2 RBD and block the ACE2 interaction
could be an attractive therapeutic option for the prevention
and treatment of COVID-19. Nbs that primarily target
the RBD of the SARS-CoV-2 S glycoprotein for virus
neutralization were developed recently [22, 23, 24]. Highly
selected Nbs and the multivalent forms obtain high
neutralization potency comparable to, or even better than,
some of the most successful SARS-CoV-2 neutralizing
mAbs. One of the aerosolized Nbs is Pittsburgh inhalable
Nanobody 21 (PIN-21), which efficiently blocked SARSCoV-2 infectivity at low doses in vitro [25]. Aerosol and
intranasal delivery of PIN-21 was also shown to be effective
to prevent and treat COVID-19 [26]. But before moving
into human clinical trials, further preclinical analyzes are
needed.
2.1.4. Miniproteins
Miniproteins, each with about 60 amino acids, are
produced to block protein-protein interactions. Recently,
miniproteins that can bind tightly to the SARS-COV-2’
S protein and block it from attaching to the ACE2
receptor was described [27]. Potential advantages of these

RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to 4 hospital with COVID-19 (RECOVERY): a randomised,
controlled, open-label, platform trial. medRxiv preprint 2021; doi: https://doi.org/10.1101/2021.06.15.21258542. [accessed 16 June 2021].
4

O’Brien MP, Forleo-Neto E, Sarkar E, Isa F, Hou P, et al. Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection. medRxiv
preprint 2021; doi: https://doi.org/10.1101/2021.06.14.21258569. [accessed 16 June 2021].
5

Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management
of Patients with COVID-19. Infectious Diseases Society of America 2021; Version 4.3.0. Website https://www.idsociety.org/practice-guideline/covid-19guideline-treatment-and-management/. [accessed 16 June 2021]
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miniproteins over antibodies are as follows: resistance
to viral mutational escapes, not requiring a cold storage
condition, possibility of a gel or aerosol formulation, and
easier production steps [27,28]. But before clinical studies,
miniproteins also need to be evaluated properly in the
preclinical studies.
2.1.5. Human soluble ACE-2
Human recombinant soluble ACE2 (hrsACE2)
theoretically should be of benefit in COVID-19 by
binding S protein and thereby neutralizing SARS-CoV-2
and by minimizing injury to multiple organs because of
renin–angiotensin system hyperactivation and increased
angiotensin II concentrations. In a phase 2 clinical trial,
hrsACE2 has been tested in patients with acute respiratory
distress syndrome (ARDS) and was shown to has an
acceptable safety profile [29]. It was also shown to reduce
SARS-CoV-2 load by a factor of 1000–5000 in-vitro cellculture [30]. Finally, a case of severe COVID-19 was
treated successfully with hrsACE2 [31].
A phase 2 clinical trial of hrsACE2 compared to
placebo (NCT04335136) in 178 patients with severe
COVID-19 was completed (NCT04335136), and the
results were shared via press release: It was reported that
all-cause mortality or invasive mechanical ventilation was
lower among patients treated with hrsACE2 compared to
placebo, but the difference was not statisticaly significant.
HrsACE2 also demonstrated a positive impact on
biomarkers of the renin angiotensin system7.
2.1.6. ACE2 receptor trap molecules
ACE2-like molecules like CTC-445.2d can be used as
decoys for the S protein and could draw SARS-CoV-2
away from cells. CTC-445.2d which developed recently is
a miniprotein that mimics ACE2, binds firmly to spike and
neutralize SARS-CoV-2. It can simultaneously bind to all
three RBDs of a single spike protein. CTC-445.2d potently
neutralized SARS-CoV-2 infection of cells in vitro, and
a single intranasal prophylactic dose of decoy protected
Syrian hamsters from a subsequent lethal SARS-CoV-2
challenge [32].
Another receptor trap molecule described by other
researchers was also neutralized
SARS-CoV-2 infections as effectively as high-affinity
antibodies isolated from convalescent patients and also
binds S proteins of other human coronaviruses. As ACE2
receptor traps have large binding interfaces, they are able
to block the entire receptor binding interface, which limits
the impact of viral escape mutations [33].
2.2. Inhibitors of fusional entry of virus
Host peptidases (furin, TMMPRS2, catepsin L) and some
host proteins (NRP1) are critical for SARS-CoV-2 entry
and act either as receptors for the attachment of the virion

S protein to the target cell (like ACE2 and NRP1) or as
facilitators of virion envelope fusion with the target cell
membrane (like furin, TMPPRS2, and catepsin L).
SARS-CoV-2 entry into host cells takes place either by
receptor-mediated endocytosis or by membrane fusion.
The binding of SARS-CoV-2 to the cellular receptor
ACE2 can result in virion uptake into endosomes. The S
protein is activated by cysteine peptidase cathepsin L in
endolysosomes. In membrane fusion, precleavage of the
spike at the polybasic S1/S2 sites by furin protease during
viral egress is needed. Studies with SARS-CoV-2 show
that this cleavage promotes subsequent virus infection.
After that processing, TMPRSS2 cleaves spike at S2ʹ and
facilitates early entry at or near the cell surface, as opposed
to late entry through the endosome [34,35,36]. This route
especially important for lung cells, which fail to express
robust levels of cathepsin L. Furin cleavage at the S1-S2
junction also exposes the C-end rule peptide on SARSCoV-2 S1 and allows binding to neuropilin-1 (NRP1),
which may facilitate the entry of the SARS-CoV-2 into
host cells and may act as a host cell mediator that can
increase the infectivity and may, thus, contribute to the
tissue/ organ tropism of this coronavirus [37,38]. Either
way, the RNA genetic material of the virus is released, and
the late stage of the life cycle subsequently takes place by
RNA replication (Figure).
That’s why both host proteases furin and TMPRSS2
and host protein NRP1 are regarded as a potential drug
targets [39]. Whilst inhibition of TMPRSS2 protease
activity would not prevent infection via the endosome,
using this pathway is detrimental to virus replication in
airway cells [40].
2.2.1.TMPRRS2 inhbitors
Camostate mesilate, nafomastat: Camostate mesilate
originally developed in the 1980s in Japan and licensed
for the treatment of chronic pancreatitis is an inhibitor
of TMPRSS2. It was shown to block SARS-CoV-2 entry
into lung cells in vitro [39] and to be a potent antiviral
agent against SARS-CoV in vivo [41]. In a case-series of
severe COVID-19 patients, camostat showed a clinical
benefit in reducing the SOFA score [42]. But in an RCT
of 137 patients hospitalized with confirmed SARS-CoV-2
infection, comparing the placebo, camostat mesilate
200 mg three times daily for 5 days did not reduce the
time regarding clinical improvement and mortality
[43]. Another clinically approved TMPRSS2 inhibitor,
nafamostat, requires intravenous dosing and has also
shown effect SARS-CoV-2 in vitro [39], but there isn’t any
clinical study about the effectiveness of nafamostat for
treating COVID-19 at the moment.

Apeiron Biologics. APEIRON’s APN01 shows clinical benefits for severely ill COVID-19 patients in phase 2 trial. Website https://www.apeiron-biologics.
com/apeirons-apn01-shows-clinical-benefits-for-severely-ill-covid-19-patients-in-phase-2-trial/[accessed 16 June 2021].
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As camostate mesilate or other TMPRSS2 inhibitors
administered in higher doses or during the very early
phase of COVID-19 might be effective in lowering the risk
of disease progression, additional studies are needed.
2.2.1.1.Antiandrogens (dutasteride, proxolutamide)
Considering that the activated androgen receptor
regulates transcription of TMPRSS2 gene, androgen
hormone receptors signaling antagonists could be
explored as treatment strategies against COVID-19 for
their role in downregulating TMPRSS2. In this regard,
it was assumed that men receiving androgen receptor
signaling or androgen inhibitors for prostate cancer,
prostate hyperplasia, or androgenic alopecia could have
reduced risk of SARS-CoV-2 infection or severity [44].
Protection from more severe COVID-19 with the use of
antiandrogens have shown in some observational studies
[45].
In an RCT of 77 outpatients with mild/moderate
confirmed COVID-19, 5-alpha-reductase inhibitor
dutasteride, which is commonly prescribed antiandrogens
for androgenic alopecia or benign prostatic hyperplasia was
found to be related to higher virologic response, clinical
recovery rate, and mean oxygen saturation compared to
the placebo group on the seventh day of treatment [46].
An
androgen
receptor
signaling
inhibitor
proxalutamide was also investigated in 3 RCTs for its
effectiveness in treating COVID-19. In the first RCT,
the rate of hospitalization and requiring mechanical
ventilation were significantly lower in men treated with
proxalutamide compared to standard of care among 214
mild/moderate confirmed COVID-19 male outpatients8.
In the second RCT which included 236 mild to
moderate confirmed COVID-19 patients, viral clearance
rate on day 7 and clinical remission time was significantly
lower in patients treated proxalutamide versus placebo
[47].
In the third RCT, the results of which have not been
published yet, comparing the placebo proxulatamide
administration in the first 48 h of symptoms was found
to be related significantly with quicker clinical remission,
lower rate of hospitalization, and mechanical ventilation
requirement and mortality among 588 confirmed
COVID-19 outpatients9.
But those encouraging findings should be confirmed
with additional, larger scale RCTs.

2.2.1.2.Bromhexine
Bromhexine is another potent inhibitor of TMPRSS2. In
a small open-label trial, a total of 78 hospitalized patients
with probable COVID-19 were randomized to bromhexine
and standard treatment arm; there was a significant
reduction in ICU admissions and death in the bromhexine
treated group compared to the standard group [48].
But in another open label RCT of 100 hospitalized
confirmed COVID-19 patients, there were no differences
observed in the clinical improvement time, the mean
intensive care unit stay, or risk of death by day 28 between
the bromhexine and standard treatment arms [49].
Finally, in another RCT, bromhexine was found to be
effective for protecting sypmtomatic COVID-19 among 50
healthcare workers, the results of the study have not peer
reviewed yet10.
As the results of published studies are conflicting, more
and larger scale RCTs are needed to define the place of
bromhexin in COVID-19 treatment.
2.3. Inhibitors of endosomal entry
2.3.1. Hydroxychloroquine
Hydroxychloroquine (HCQ) is an aminoquinoline, which
has been used to treat malaria and autoimmune diseases
for over 50 years. Despite preliminary in vitro studies
in kidney-derived Vero E6 cells reported that HCQ is
effective against SARS-CoV-2, probably by inhibiting viral
transport in endosomes by alkalinizing the intra-organel
compartment; later studies in the TMPRSS2-expressing
human lung cell line Calu-3 did not replicate these results.
This was because, instead of endosomal pathway that HCQ
inhibits, SARS-CoV-2 primarly uses fusion pathway in
which TMPRSS2 activates it for entry into lung cells [50].
HCQ has been the most studied drug for the treatment
and prevention of COVID-19 since the beginning of the
pandemic and more than 120 clinical RCTs using HCQ
were registered in the trial registries [51].
Unfortunately, in a metaanalysis of 14 unpublished
(including1308 patients) and 14 published (including
9011 patients) RCTs, HCQ was found to be associated
with increased mortality in COVID-19 patients with a
combined OR of 1.11 (95% CI: 1.02–1.20; I² = 0%) for allcause mortality and no subgroup effects were found [52].
Additionally, in another metaanalysis of six RCTs
of prophylactic hydroxychloroquine usage (n = 6059
participants), it was found that compared with standard
care or placebo, HCQ has no effect on suspected, probable,

Cadegiani FA, McCoy J, Wambier CG, et al. Proxalutamide (GT0918) Reduces the Rate of Hospitalization and Death in COVID-19 Male Patients: A
Randomized Double-Blinded Placebo-Controlled Trial.Research Square Preprint 2020. DOI: 10.21203/rs.3.rs-135303/v1. [accessed 16 June 2021].
8
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COVID-19 Patients, March, 11, 2021. Website https://www.biospace.com/article/releases/kintor-pharmaceutical-announces-results-from-investigatorinitiated-brazil-trial-demonstrating-92-percent-reduction-in-mortality-in-hospitalized-covid-19-patients/[accessed 16 June 2021].
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or laboratory-confirmed SARS-CoV-2 infection or does
not reduce the risk of laboratory-confirmed SARS-CoV-2
infection [53].
As a result, current guidelines recommend against
HCQ among hospitalized patients with COVID-19 with
a strong recommendation and moderate certainty of
evidence6.
2.3.2. Umifenovir
Umifenovir is a broad-spectrum antiviral agent which
could effectively inhibit the fusion of virus with host cells
and is already licensed for prophylaxis and treatment of
influenza. Previous research has revealed that
umifenovir is an efficient inhibitor of SARS-CoV-2 in
vitro. Nevertheless, little is known about the actual clinical
efficacy of umifenovir in vivo.
Umifenovir is an antiviral agent which could inhibit the
fusion of the virus with host cells and is already licensed
for prophylaxis and treatment of influenza in Russia and
China. It was shown that umifenovir inhibits SARS-CoV-2
in vitro with a 50% effective concentration (EC50) of 4.11
μM [54].
But in a metaanalysis of 12 clinical studies with 1052
patients, compared with the control group, umifenovir was
not associated with lower risk of admission to intensive
care unit or mechanical ventilation or death (RR:1.20; 95%
CI: 0.61 to 2.37), a lower rate of symptoms alleviation on
day 7, or lower hospital length of stay (MD: 1.34; 95% CI:
–2.08 to 4.76) [55].
As a result, there is no evidence to support the use of
umifenovir for patients with COVID-19.
2.3.3.Nitazoxanide
Nitazoxanide, a small-molecule anti-protozoal drug is
currently recommended for treating diarrhea caused
by Cryptosporidium spp. or Giardia spp. Nitazoxanide
targets against numerous points of SARS-CoV-2 life cycle
including an endosomal and fusional entry into the host
cells [56]. In the analysis of the key secondary endpoint,
treatment with NT-300 was associated with an 85% (0.5%
of NT-300-treated patients versus 3.6% of patients treated
with placebo) reduction in the progression to severe
illness11. The number of clinical trials was registered using
nitazoxanide as the only drug or in combination with other
antivirals for the treatment of patients with COVID-19
(NCT04486313, NCT04552483, NCT04348409), and
results will be released soon.

2.3.4. Niclosamide
Niclosamide, which has been used to treat intestinal worms,
also exhibits highly potent activity against SARS-CoV-2 in
a Vero cell and human airway infection model [57]12 and
inhibits SARS-CoV2 entry by blocking internalization
through pH-dependent endocytic pathway13. The novel
formulation demonstrates potent in vitro and in vivo
activity against SARS-CoV-2 [58].
Another investigator from Denmark also developed a
formulation of niclosamide optimized for inhalation and
intranasal application called UNI91104, which is welltolerated in healthy volunteers in phase1 clinical study
[59].
Inhaler and nasal formulation of niclosamide are
promising candidates for the treatment of viral respiratory
infections such as COVID19. Further phase 1 and other
clinical trials are being planned [59].
2.4. Heparan sulfate proteoglycan inhibitors: lactoferrin
It was shown in recent studies that in addition to ACE2,
heparan sulfate proteoglycans (HSPGs) also has an
important role in SARS-CoV-2 cell attachment [6, 59].
geLactoferrin showed a broad-spectrum antiviral
activity against SARS-CoV-2, HCoV-OC43, HCoV-NL63,
and HCoV-229E in cell culture via binding HSPGs and
blocking viral attachment to the host cell. In cell culture,
combination lactoferrin with remdesivir was found to have
a synergistic effect against SARS-CoV-2. [60]. Further
studies are needed to define the place of lactoferrin in the
treatment of COVID-19.
3. Inhibitors of viral proteases
Proteases catalyze their own release and liberate other
nonstructural proteins (Nsps) from the polyprotein,
building a replicase–transcriptase complex (RTC) that is
vital for viral transcription and replication [36]. Both Mpro
and PLpro are essential for viral replication, making them
attractive targets for drug development. The high level of
structural conservation among the Mpros of 12 different
CoVs could give a chance to design a pan-coronavirus
inhibitor of viral proteases, and target-specific inhibitors
also could be developed for the SARSCoV-2 Mpro [61].
In addition, Mpro has no human homolog. The above
features make it an attractive drug target against CoVs.
3.1. Lopinavir/ritonavir
Lopinavir and ritonavir were the first drugs used in the
clinical trials to treat COVID-19 targeting Mpro. Although

Romark, 2021. Romark announces ınıtıal results of phase 3 clınıcal trıal of nt-300 tablets for the treatment of covıd-19. Website https://www.romark.
com/romark-announces-initial-results-of-phase-3-clinical-trial-of-nt-300-tablets-for-the-treatment-of-covid-19/[accessed 16 June 2021].
11

Weiss A, Touret[accessed 16 June 2021]. F, Baronti C, et al. Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2
infection and a conserved potency against the UK B.1.1.7 and SA B.1.351 variant. bioRxiv 2021. DOI: 10.1101/2021.04.26.441457. [accessed 16 June
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lopinavir/ritonavir showed inhibitor effects against SARSCoV-2 in Vero E6 cells with an estimated EC50 of 26.63
μM [62], in three RCTs among hospitalized patients with
COVID-19, treatment with lopinavir/ritonavir has failed to
show any beneficial effect on mortality or need for invasive
mechanical ventilation or 28-day hospital discharge
rates [63, 64, 65]. Whether lopinavir-ritonavir has a role
in outpatients with the nonsevere disease is uncertain,
it should be used in outpatients only in the context of a
clinical trial. Lopinavir-ritonavir is highly protein-bound
and does not appear to achieve plasma levels close to the
defined EC50 [66, 67].
Current guidelines are against the use of the
combination lopinavir/ritonavir among hospitalized
patients with COVID-196.
3.2. GC-376
A number of Mpro inhibitors are in different stages
of preclinical and clinical development. GC-376 is a
representative Mpro inhibitor that has shown antiviral
activity against feline infectious peritonitis (FIP) CoV in
experimentally infected cats. GC-376 showed promising
antiviral activity against the SARS-CoV-2 virus with an
EC50 of 3.37 µM [68] and was found to increase survival
in MERS-CoV–infected mice [69].
Antiviral activity of GC-376 was also shown in SARSCoV-2-infected K18hACE2 mice, although it was modest
consisted with its moderate in vitro antiviral activity. In
comparison, a GC-376 analog 6j was recently reported
to improve survival in MERS CoV-infected mice, and
the EC50 value of the in vitro cellular antiviral activity
of 6j against MERS-CoV was 0.04±0.02 µM. This result
suggests that in vitro cellular antiviral activity of GC-376
against SARS-CoV-2 needs to be improved by 10–100-fold
to achieve desired in vivo antiviral efficacy [70].
3.3. PF-07304814 and PF-07321332
PF-00835321 and its novel designed phosphate prodrug
PF-07304814 are potent inhibitors of the coronavirus
family Mpro in vitro, with selectivity over human host
protease targets.
It was first developed for SARS in 2003, but there wasn’t
any chance to fully optimize it for clinical use because of
the end of the epidemic. When SARS-CoV-2 came along
and genomic analyses revealed that the virus’s Mpro
protein was almost identical to that from the original
SARS pathogen, studies were started for COVID-19, and
preclinical studies revealed that PF-00835231 exhibits
potent in vitro antiviral activity against SARS-CoV-2 with
suitable pharmaceutical properties as a single agent and is
additive/synergistic in combination with remdesivir [71]14.

The oral form of intravenously administered PF07304814 was also developed, which is named PF07321332. PF-07321332 may have inhibitory effects
against not only viral proteases but also host proteases,
which could be resulted in synergistic effects with superior
clinical efficacy15.
The oral bioavailability of PF-07321332 will be a major
advantage in the clinical management of COVID-19.
PF-07304814 (IV) and PF-07321332 (oral) entered
phase 1 clinical trials last September in hospitalized
COVID-19 patients and healthy participants, respectively
(NCT04535167, NCT04756531) [2].
4. Inhibitors of viral RNA
4.1. Viral RdRp inhibitors
4.1.1.Favipiravir
Being a guanosin purin nucleotide analogue, favipiravir
(T-705; 6-fluoro-3-hydroxypyrazine-2- carboxamine) is
metabolized intracellularly into its active ribofuranosyl
5’-triphosphate (favipiravir-RTP) metabolite. FavipiravirRTP is a potent inhibitor of RdRp of RNA viruses and
induces lethal mutagenesis. It has shown broad-spectrum
activity against variety of RNA viruses including influenza,
arenaviruses, bunyaviruses, and flaviviruses. The only oral
form of favipiravir is available and after taking orally, it is
metabolized by aldehyde oxidase in the liver and excreted
renally. Favipiravir is approved for the treatment of
epidemic new influenza viruses in Japan. It has been used
as an anti-COVID-19 drug in so many countries, including
Turkey, India, Russia with a EUA since the beginning of
the Pandemic.
It was shown to be active against SARS-CoV-2 in vitro
in Vero cells with (EC50) ranging from 62 to > 500 µM (10
to > 78 µg/mL). Mechanism of actions of favipiravir against
SARS-CoV-2 was shown to be through a combination of
chain termination, reduced RNA synthesis and lethal
mutagenesis in vitro. As it exerts stronger antiviral effect
after reaching steady state serum concentration which
takes 1 to 2 days, earlier treatment is expected to be more
effective. Embryonic lethality and teratogenicity have
been shown in animals, as a result, it should not be used
in pregnant and nursing women. Also, abstinence or
contraception should be recommended 7 days after the
end of the favipiravir treatment for males.
Recommended dosage for influenza is 1600 mg, twice
a day for the first day, 600mg twice a day for the day 2
to 5 [72–76]. But the optimal dose of favipiravir for the
treatment of COVID-19 has yet to be determined. In a
hamster model of SARS-CoV-2 infection, while low dose

Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, et al. Discovery of a novel inhibitor of coronavirus 3CL protease as a clinical candidate for
the potential treatment of COVID-19. bioRxiv [Preprint]. 2020:2020.09.12.293498. doi: 10.1101/2020.09.12.293498; [accessed 16 June 2021].
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of favipiravir resulted in no reduction in virus levels, high
doses of it significantly reduced infectious virus titers in
the lungs, markedly improved lung histopathology and
decreased virus transmission by direct contact. In that
study, the decrease of infectious virus titers was more than
the decrease of viral RNA copies. This discrepancy was
shown to be due to the mutagenic effect of favipiravir, as
the mean number of mutations in the viral RNA increased
by a factor of more than three upon favipiravir treatment.
Plasma trough concentrations to potently block virus
infection as measured in the infected hamsters may be
achievable in humans treated with favipiravir [77]. In a
clinical trial in Ebola virus-infected patients, a favipiravir
dosing scheme of 6.000 mg on day 0, followed by 1.200
mg BID for 9 days, resulted in a median plasma trough
concentration of 25.9 μg/mL at day 4 [78]. A favipiravir
dosing of 1.800 mg twice on the first day, followed by 800
mg orally twice a day achieves plasma concentration of
approximately 60μg/mL and higher in healthy individuals
[79]. But it has been reported that the trough concentrations
in critically ill COVID-19 patients are lower than those in
healthy persons and do not reach the in vitro obtained
EC50 values against SARS-CoV-2 [80, 81].
In another hamster model study, high doses of
favipiravir were found to be associated with antiviral
activity against SARS-CoV-2 infection, and the better
antiviral efficacy was observed using a preventive strategy,
suggesting that favipiravir could be more appropriate for
a prophylactic use. When treatment is initiated before or
simultaneously to infection, favipiravir has a strong dose
effect, leading to reduction of infectious titers in lungs
and clinical alleviation of the disease. But the highest dose
of favipiravir tested is associated with signs of toxicity in
animals. Thereby, pharmacokinetic and tolerance studies
are required to determine whether similar effects can be
safely achieved in humans. Lung penetration of favipiravir
in hamsters has been shown to be efficient, resulting in
lung/plasma ratios of 35 to 44% after repeated dosing.
However, it is not known whether the lung penetration in
humans is similar to that in hamsters [82].
In an exploratory RCT, favipiravir didn’t demonstrate
significant in vitro antiviral activity up to 100 μM and under
a dosage of 1600 mg or 2200mg loading and 3X600 mg/
day maintenance, the insufficient exposure of favipiravir
resulted in no additional antiviral benefit among patients
with COVID-19 [83]. Low loading dose of favipiravir (≤45
mg/kg/day) was identified as a poor prognostic factor for
early clinical improvement in a clinical trial from Tailand16

as a result administration of appropriate loading and
maintenance doses of favipiravir are of utmost importance.
The results of clinical studies of favipiravir for the
treatment of COVID-19 were conflicting. In an earlier
metaanalysis, the pooled analysis of five studies showed
that favipiravir was associated with a higher clinical
improvement rate than control group, but the difference
was not statistically significant (odds ratio [OR], 1.54;
95% CI, 0.78–3.04); viral clearance rate at day 4–5, 7-8
and 10–12 was also not different between favipiravir and
comparator, additionally the risk of adverse event was
similar between groups [84].
But in another recent metaanalysis of 9 studies
comparing the efficacy of favipiravir with other control
groups revealed a significant clinical improvement in the
favipiravir group versus the control group during seven
days after hospitalization (RR = 1.24, 95% CI: 1.09–1.41;
p = 0.001). Although viral clearance was more in 14 days
after hospitalization in favipiravir group, this finding was
not statistically significant (RR = 1.11, 95% CI:0.98–1.25;
p = 0.094). The need for supplemental oxygen therapy
was found to be 7% less in the favipiravir group than the
control group, (RR = 0.93, 95% CI: 0.67–1.28; p = 0.664).
ICU transfer and adverse events were not statistically
different between the groups. Finally, the mortality rate
was found to be 30% less in the favipiravir group, but,
again, this finding was not statistically significant [85].
In another recent metaanalysi, among 5 studies
included a comparator group, the favipiravir group
showed significantly better viral clearance on day 7 after
the initiation of treatment (odds ratio [OR] = 2.49, 95%
confidence interval [CI] = 1.19–5.22), but there was no
difference on day 14 (OR = 2.19, 95% CI = 0.69–6.95).
Clinical improvement was significantly better in the
favipiravir group on days 7 and 14 with an OR of 1.60, 95%
CI = 1.03–2.49, and 3.03, 95% CI = 1.17–7.80, respectively
[86].
Unfortunately, all of the studies included in those
metaanalyses have varied designs and comparators and
the low number of patients; as a result, their findings are
based on the analysis of data with high heterogenicity.
That’s why further large scale randomized, double blind
trials are needed to be done to define the role of favipiravir
in the treatment of COVID-19.
In the single-blinded phase III RCT trial of Japan17, 156
patients with COVID- 19 with nonsevere pneumonia were
included, favipiravir met the primary end point, which
was time to viral clearance and to alleviation of symptoms.
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The results were 11.9 days and 14.7 days for the favipiravir
and the placebo groups, respectively (P =0.0136). But, after
reviewing these data, favipiravir was not approved for the
use for COVID-19 by the Japan Pharmaceutical Affairs
and Food Sanitation Council (PAFSC) because of the
single-blinded design of the study, the uncertain primary
outcome and the founded biases between the groups.
Approval of favipiravir in Japan would be reevaluated
after the results of forthcoming ongoing clinical trials
conducted in Kuwait and United States [87].
Double- blind phase-III trial in Kuwait was terminated
on January 27, 2021, because interim analysis of the
study involving 353 patients hospitalized with moderate
to severe COVID- 19, did not show a statistically
significant difference for the clinical recovery between
favipiravir and placebo (7 versus 8 days, p > 0.05). But, the
subgroup analysis of the low-risk study cohort (n = 181)
demonstrated a 3 day earlier discharge in the favipiravir
group compared to the placebo group (8 days versus 11
days; p = 0.0063) for time to hospital discharge.
The subgroup analysis data during the initial interim
analysis points towards the hypothesis with clinically
significant insights from this study that an antiviral
drug such as favipiravir may be effective as part of early
treatment initiation in COVID-19 patients and not
effective in the late-stage hospital treatment for moderate
and severe COVID-19 patients18. Another phase III
ongoing pivotal study of favipiravir (PRESCO study) for
patients with COVID- 19 with mild to moderate symptoms
in the United States are planned to include 826 patients19.
After interim analysis of 600 participitants on May 17,
2021, the Data and Safety Monitoring Board reported no
safety issues; as a result, the study will continue without
modification and is expected to be completed in the third
quarter of 202120. Favipiravir is also being investigated
as a treatment option for COVID-19 among outpatients
in an arm of PRINCIPLE (The Platform Randomised
trial of Interventions against COVID-19 In older) RCT’s
in the UK. People aged 50 to 64 with certain underlying
health conditions or shortness of breath from COVID-19,

or aged over 65, are eligible to join the favipiravir arm
of PRINCIPLE within the first 14 days of experiencing
COVID-19 symptoms21.
With the results of these final studies, the effectiveness
of favipiravir in the treatment of COVID-19 will be defined
more clearly by the end of 2021.
Additional clinical studies are needed to define the
effectiveness of favipiravir at different dosages or at
different stages of COVID-19 and PK of favipiravir should
be thoroughly evaluated in those patients.
4.1.2.Remdesivir
Remdesivir is a prodrug of adenosine nucleotide
analog that is intracellularly metabolized to an analog
of adenosine triphosphate that inhibits viral RdRp. It
was originally developed for the treatment of Ebola and
Marburg virus infections. Remdesivir has broad spectrum
activity against members of several virus families,
including filoviruses (e.g., Ebola) and coronaviruses (e.g.,
SARS-CoV and MERS-CoV) and has shown prophylactic
and therapeutic efficacy in nonclinical models of these
coronaviruses. In vitro testing has also shown that
remdesivir has an activity against coronoviruses including
SARS-CoV, MERS-CoV and SARS-CoV-2 with an EC50
value of 0.09 μM, 0.18 μM and 0.77 μM, respectively [8890]. Being a monophosphoramidate prodrug, remdesivir
is metabolized to its active form, GS-441524 and is
recognized as a substrate by RdRp and causing premature
termination of viral RNA transcription. It shows resistance
to exonucleases of coronaviruses [88]
In a macaque model, unlike vehicle-treated animals,
macaques treated early with remdesivir did not show
signs of respiratory disease; they also showed reduced
pulmonary infiltrates on radiographs and reduced virus
titres in bronchoalveolar lavages 12 h after the first dose.
But virus shedding from the upper respiratory tract was
not reduced by remdesivir treatment [91].
A metaanalysis of 4 RCTs with 7333 participants about
the effectiveness of remdesivir on COVID-19 [65, 92, 93,
94] found no evidence that remdesivir improved outcomes
that matter to patients such as reduced mortality, need
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for mechanical ventilation, time to clinical improvement
and others. However, the low certainty evidence for
these outcomes, especially mortality, does not prove
that remdesivir is ineffective; rather, there is insufficient
evidence to confirm that it does improve patient-important
outcomes with an odds ratio (95%CI) 0.9 (CI 95%
0.7–1.12); 0.89 (CI 95% 0.76–1.03); 1.06 (CI 95% 0.06–
17.56) and 1 (CI 95% 0.37–3.83), for 28 days mortality;
mechanical ventilation; viral clearance at day 7; serious
adverse events leading to discontinuation respectively22. As
a result, WHO suggests against administering remdesivir
in addition to usual care among hospitalized patients with
COVID-19 infection, regardless of the severity of the
disease22.
But IDSA suggests treatment with 5 days of remdesivir
only for patients with COVID-19 on supplemental oxygen
but not on mechanical ventilation or ECMO or, without
the need for supplemental oxygen and oxygen saturation
>94% on room air, as a conditional recommendation and
very low certainty of evidence5. In the pooled analysis of
RCT’s about the effectiveness of remdesivir for patients
with COVID-19 on supplemental oxygen but not on
mechanical ventilation or ECMO [65, 92, 93], Infectious
Disease Society of America (IDSA) also could not find
any statistically significant mortality (RR: 0.92; 95% CI:
0.77, 1.10) or clinical improvement benefit at day 28, but
they find that patients receiving treatment with remdesivir
trend toward greater clinical improvement at 28 days than
patients not receiving remdesivir (RR: 1.13; 95% CI 0.91–
1.41).
In addition, based on a post-hoc analysis of patients
with severe COVID-19, they find that receiving treatment
with remdesivir had a shorter median time to recovery
(median 11 versus 18 days; Rate ratio: 1.31; 95% CI: 1.12,
1.52) and decreased need for mechanical ventilation (RR:
0.57; 95% CI: 0.42, 0.79)6.
Current findings of the effectiveness of remdesivir for
the treatment of patients for COVID-19 are conflicting,
additionally the IV route of administration of remdesivir
prevents its widespread usage for the treatment of
COVID-19.
4.1.3. Molnupiravir
Molnupiravir (MK-4482/EIDD-2801) is the orally
available pro-drug of the nucleoside analogue N4hydroxycytidine (NHC), which has broad-spectrum
anti-RNA virus activity including influenza ebola, CoV,
respiratory syncytial virus, and Venezuelan equine
encephalitis virus (VEEV). Serial passaging in the presence
of NHC led to low level resistance for VEEV but not RSV,
22

influenza A virus, and bovine viral diarrhea virus, thus,
indicating a high resistance barrier [95]. NHC was found
to be potently antiviral with an IC50 of 0.08 mM and
IC50 of 0.024 mM against SARS-CoV-2 in the Calu-3 cells
and human airway epithelial cells, respectively. It was also
shown to has a broad-spectrum antiviral activity against
MERS-CoV, SARS-CoV, and related zoonotic group
2b or 2c bat-CoVs, as well as increased potency against
a CoVs bearing resistance mutations to the nucleoside
analog inhibitor remdesivir. Its effect was found to be
associated with increased transition mutation frequency
in viral but not in host cell RNA. Both prophylactic and
therapeutic administration of molnupiravir improved
pulmonary function and reduced virus titer and body
weight loss in mice infected with SARS-Cov-2. The
potency of molnupiravir against multiple CoVs and oral
bioavailability highlights its potential utility as an effective
antiviral against SARS-CoV-2 and other future zoonotic
CoVs [96].
In a ferret model, therapeutic treatment of infected
animals with twice-daily molnupiravir significantly
reduced upper respiratory tract SARS-CoV-2 load and
completely suppressed spread to untreated contact
animals, and it was seen that earlier treatment of ferrets
with molnupiravir was more beneficial [97].
Single and multiple doses of molnupiravir were
evaluated in a phase I randomized, double-blind, placebocontrolled study in healthy volunteers, and demonstrated
good tolerability and dose-proportional pharmacokinetics
with relatively low variability following administration to
healthy volunteers at clinically relevant doses23.
Based on a planned interim analysis of data from
the Phase II/III trials, the decision has been made
to proceed with the Phase 3 portion of the study in
outpatients (MOVeOUT), but not in hospitalized patients
(MOVeIN) with COVID-1. This is because the data from
hospitalized patients indicate that molnupiravir is unlikely
to demonstrate a clinical benefit in hospitalized patients,
who generally had a longer duration of symptoms prior to
study entry. In an interim analysis of MOVe-OUT study,
the percentage of patients who were hospitalized and/or
died was lower in the molnupiravir-treated groups versus
the placebo arm, but the difference was not statistically
significant. Nasopharyngeal SARS-CoV-2 clearance
rate was higher in molnupiravir treated patients than in
placebo group (6/25 versus 0/47) at day 5 of treatment (p =
0.001). These differences in virology endpoints were more
pronounced in participants enrolled <5 days following

WHO, Therapeutics and COVID-19: living guideline – World Health Organization (WHO), 31 March 2021. [accessed 16 June 2021].

Painter WP, Holman W, Bush JA, Almazedi F, Malik H, et al. Human Safety, Tolerability, and Pharmacokinetics of a Novel Broad-Spectrum Oral
Antiviral Compound, Molnupiravir, with Activity Against SARS-CoV-2. medRxiv preprint 2020; doi: https://doi.org/10.1101/2020.12.10.20235747
[accessed 16 June 2021].
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symptom onset. After enrolment of 1850 patients, the final
results of MOVeOUT study are expected by Agust, 202124.
In addition to Phase-3 RCT, it is planned to initiate
a clinical trial to evaluate molnupiravir for postexposure
prophylaxis in the second half of 2021.
4.1.4. AT-527
AT-527 is an orally available prodrug of a guanosine
nucleotide analog that has demonstrated potent in
vitro activity against clinical isolates of hepatitis C virus
(HCV) and found to be effective in the treatment of
HCV-infected patients [98]. AT-511, the free base of
AT-527 also has potent antiviral activity in vitro against
several human coronaviruses, including SARS-CoV-2.
The active triphosphate metabolite of AT-527, AT9010, which cannot penetrate to cell membranes and is
formed only after intracellular delivery of the prodrug,
is produced in substantial amounts in primary human
cells of the respiratory tract incubated with AT-511. In
normal human airway epithelial cells, the concentration
of AT-511 required to inhibit replication of SARS-CoV-2
by 90% (EC90) was 0.47mM, very similar to its EC90
against human coronavirus (HCoV)-229E, HCoVOC43, and SARS-CoV in Huh-7 cells. After oral dosing,
the predicted concentration of the active metabolite in
pulmonary tissue suggests that AT-527 may be an effective
treatment option for individuals infected with COVID-19
[99]. AT-9010 simultaneously binds to both NIRAN and
RdRp active site of nsp12 and blocking their respective
activities, which should attenuate the chance of resistance
mutations25.
The ongoing phase II and III clinical trials
(NCT04709835, NCT04396106, NCT04889040) of AT527 for the treatment of both out and in patients with
COVID-19 are expected to be completed at the end of
2021.
4.2. Inhibitors of host proteins supporting viral RNA
synthesis
4.2.1. Inhibitors of inosine monophospate dehydrogenase
(IMPD): Merimepodib
IMPD is an enzyme responsible for de novo synthesis
of guanosine nucleotides that SARS-CoV-2 needs it
during transcription in the host cell. Merimepodib
noncompetitively inhibits IMPD and, inhibited SARSCoV-2 with concentrations as low as 3.3 μM in Vero cells
[100]. But a phase 2 RCT of merimepodib in combination
with remdesivir in adult patients with severe COVID-19
was terminated because of the failure to meet the primary
endpoint (NCT04410354).

4.2.2. Inhibitor of dihydroorarate dehydrogenase:
PTC299
Human dihydroorotate dehydrogenase (DHODH) is a
key enzyme of pyrimidine de novo biosynthesis pathway.
SARS-CoV-2 hijacks that pathway to replicate. A DHODH
inhibitor, PTC299 which was originally designed as oral
drug for acute myeloid leukemia- manifested robustly,
dose-dependent, inhibition of SARS CoV-2 replication
with an EC50 range of 2.0 to 31.6 nM on Vero-cells [28,
101].
4.3. Cas13a
A gene-editing enzyme Cas 13a could seek out and cuts
RNA in to pieces. A Cas13a enzyme targeted to 2 SARSCoV-2 genes encoding the RdRp and the N protein has
been developed and was reduced SARS-CoV-2 replication
and reduced symptoms in a hamsters models of the
COVID-19 [102].
5. Inhibitors of host proteins supporting viral protein
synthesis (Inhibitors of eEF1A (plitidepsin); inhibitors
of ER chaperon protein (S1R) (fluvoxamin))
There are important advantages of targeting the host
proteins, which include creating a higher barrier for
viruses to develop resistance and broader protection
against diverse viral strains [103].
Among numerous host proteins that play a role in the
viral life cycle of SARS-CoV-2, those targeted the eukaryotic
translation machinery demonstrated particularly potent
antiviral activities. Zotatafin, an inhibitor of eukaryotic
translation initiation factor 4A (eIF4A); plitidepsin, an
inhibitor of eukaryotic translation elongation factor 1a
(eEF1A), and ternatin-4, also an inhibitor of eEF1A show
antiviral activity against SARS-CoV-2. Among those
plitidepsin is the most effective.
5.1. Plitidepsin
Plitidepsin was found to be more potent than remdesivir
tested in the human pneumocyte-like cells line by a factor
of 27.5 and treatment of mice with plitidepsin reduced viral
lung titers and lung pathology upon infection to a similar
degree as remdesivir [104]. There are concerns about the
use of translation inhibitors, because of potential toxicities
arising from the systemic inhibition of host translation.
But plitidepsin was evaluated in many cancer clinical trials
and the safety profile is well established [105].
A phase I/II clinical study of plitidepsin for the treatment
of COVID-19 has been completed (NCT04382066),
and zotatifin, is also in clinical trials for the treatment of
COVID-19 (NCT04632381). Results of plitidepsin’s Phase
I/II has not been published yet but promising results

Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir.
Website https://www.businesswire.com/news/home/20210305005610/en/. [accessed 16 June 2021].
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were released [105]. The ongoing phase III clinical trial
(NCT04784559) will show whether plitidepsin is effective
for COVID-19. The study is expected to be completed in
November, 2021.
5.2. Fluvoxamin
It was previously suggested that antidepressants may
be associated with decreased plasma levels of some
inflammatory mediators [106]. A selective serotonin
reuptake inhibitor, fluoxetine was shown to have antiviral
activity against SARS-CoV-2 with an EC50 level off 0.387
µg/ml in Vero and Huh7 cell and to inhibit SARS‑CoV‑2
in human lung tissue [107].
In an observational study, antidepressant use was
found to be associated with reduced risk of intubation and
death in patients hospitalized for COVID-19 [108].
In a preliminary RCT of 52 COVID-19 patients, clinical
deterioration rate was lower in the fluvoxamine group
than in the placebo group (absolute difference, 8.7% [95%
CI, 1.8%–16.4%], p = 0.009) [109]. Potential mechanisms
suggested for the effect of fluvoxamine in COVID-19 were
ER chaperon protein sigma-1 receptor (S1R) agonism and
functional inhibition of acid sphingomyelinase activity
(FIASMA), which were shown to prevent the infection of
epithelial cells with SARS-CoV-2 [110].
The larger randomized trials with more definitive
outcome measures are required to define the role of
fluvoxamine in the treatment of COVID-19.
6. Inhibitors of viral immunomodulation (Inhibitors of
host importin α/β (ivermectin)
6.1. Ivermectin
Ivermectin is an FDA-approved broad-spectrum
antiparasitic agent, it has shown to have antiviral activity
against a broad range of viruses in vitro in recent years.
Ivermectin has been shown to inhibit the nuclear import
of host and viral proteins. In an in vitro study, ivermectin
was found to be an inhibitor of the SARS-CoV-2, with a
single addition to Vero-hSLAM cells 2 h postinfection
with SARS-CoV-2 able to effect ~5000-fold reduction in
viral RNA at 48 h. Authors hypothesize that this was likely
through inhibiting IMPα/β1- mediated nuclear import of
viral proteins (as shown for other RNA viruses), and this
inhibition disrupts the immune evasion mechanism of the
virus [111]. But, after analyzing published pharmacokinetic
data from clinically relevant and excessive dosing studies,
it was concluded that the SARS-CoV-2 inhibitory
concentrations are not likely to be attainable in humans
[112, 113].
16 RCTs with 2407 patients having either severe or
non-severe COVID-19 were evaluated in a systematic
review of WHO, and it was seen that only five studies
directly compared ivermectin with standard care and
reported mortality. While pooled estimate of those five
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RCTs suggests a reduction in mortality with ivermectin,
this effect was not apparent if only the trials at low risk of
bias were considered. In addition to concerns about the
risk of bias, serious concerns related to imprecision for
the outcome of mortality were noticed. Furthermore, the
evidence informing this comparison was from multiple
small trials, adding to the risk of unrecognized imbalances
in study arms. Given the strong likelihood that chance
may be playing a role in the observed findings, the WHO
panel suggest that there was very serious imprecision,
further lowering the overall certainty in findings. They
concluded that there was insufficient evidence about the
effectiveness of ivermectin in treating Covid-19; there
was a large degree of uncertainty in the evidence about
ivermectin on mortality, need for mechanical ventilation,
need for hospital admission, time to clinical improvement,
and other patient-important outcomes, and there was
potential for harm with an increased risk of adverse
events leading to study drug discontinuation. As a result,
WHO recommends not to use ivermectin in patients with
Covid-19 except in the context of a clinical trial, regardless
of disease severity or duration of symptoms21.
In line with the WHO’s analysis and recommendation,
IDSA also suggested
against ivermectin for the
treatment of hospitalized patients with COVID-19,
unless in the context of a clinical trial. They also suggest
against ivermectin for the treatment of outpatients with
COVID-19, unless in the context of a clinical trial and
concluded that well-designed, adequately powered, and
well-executed clinical trials are needed to inform decisions
on treating COVID-19 with ivermectin 5.
One metaanalysis about the efficacy of ivermectin
in prophylaxis of COVID-19 included 3 studies; 2
with ivermectin alone (n = 540), and 1 with ivermectin
combined with iota-carrageenan (n = 234), all compared
with standard care or placebo. Again, serious risk of bias
and very serious imprecision, and, thus, very low certainty
of evidence was determined about the effects of ivermectin
combined with iota-carrageenan on laboratory confirmed
Covid-19 (52 fewer per 1000, 58 fewer to 37 fewer),
ivermectin alone on laboratory confirmed infection (50
fewer per 1000, 59 fewer to 16 fewer) and suspected,
probable, or laboratory confirmed infection (159 fewer
per 1000, 165 fewer to 144 fewer). They concluded that
because of serious risk of bias and very serious imprecision,
it was highly uncertain whether ivermectin combined with
iota-carrageenan and ivermectin alone reduces the risk of
SARS-CoV-2 infection [114].
7. Agents supporting host natural immunity
7.1. Interferons
All viruses trigger an antiviral response that relies
on the immediate production of IFNβ in the host.
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The binding of IFNβ to its receptor then triggers the
production of IFN-α. Both IFNs trigger the expression
of hundreds of interferon-stimulated genes (ISGs). If the
production of IFNα/β occurs immediately and is intense
enough, the infection can be stopped. This is probably
what happens for SARS-CoV-2- infected individuals
who remain asymptomatic or have mild disease, as in
almost all children. However, the virus-induced IFNα/β
response may be weak, due to immunosenescence,
comorbidities, and anti-IFN mechanisms that most
viruses have developed through evolution [7]. Recent
studies reveal that IFN dysregulation is key to determine
COVID-19 pathogenesis. Inborn errors of TLR3- and
IRF7-dependent type I IFN immunity were found to be
related to life-threatening COVID-19 pneumonia [115].
Additionally, neutralizing IgG auto-antibodies against
IFN-α2 or IFN-ω, or both were determined in 10% of
patients with life-threatening COVID-19 pneumonia, and
all of these patients tested had low or undetectable serum
IFN- α levels during acute disease [116]. In situations
of inefficient IFN response, the virus replicates and this
triggers a second inflammatory/ immune response, which
may become explosive and potentially result in a cytokine
storm and ARDS. Prophylactic administration of IFNs at
the early stage may elicit an autonomous antiviral state and
prevent COVID-19 progression [117]. But, contrary to this
hypothesis, in SOLIDARITY clinical trial, death occurred
in 243 of 2050 patients receiving interferon and in 216 of
2050 receiving control (rate ratio, 1.16; 95% CI, 0.96 to
1.39; P=0.11), and IFN did not reduce mortality, overall
or in any subgroup, or reduced initiation of ventilation or
hospitalization duration [65]. Several factors seem to affect
IFNs efficacy, including disease severity and treatment
onset time. As nearly ¾ of patients were on supplemental
oxygen at the time of randomization in the SOLIDARITY
trial, IFN treatment may be delayed for this group of
patients.
In another RCT in adults with confirmed COVID-19,
clinical recovery rate was greater in patients who received
inhaled nebulised interferon beta-1a (SNG001) placebo
(odds ratio 2·32 [95% CI 1·07–5·04]; p = 0·033) [118].
In a three-armed, RCT of IFNβ1a and IFNβ1b in patients
with confirmed SARS-CoV-2 infection, as compared with
the standard care, the benefit of a significant reduction

in clinical improvement time was observed only in the
IFNβ1a arm. This finding needs further confirmation in
larger studies [119].
Finally, in a metaanalysis of five RCT’s about the
effectiveness of IFN- β for treatment of COVID-19, the
average mortality rate was reported as 6.195% and 18.02%
in intervention and control groups, respectively. Likewise,
the median days of hospitalization were found to be lower
in the intervention group (9 days) than the control group
(12.25 days), and IFN-β was found to increase the overall
discharge rate (RR = 3.05; 95% CI: 1.09-5.01) [120].
In conclusion, IFN β could have a role in the treatment
of COVID-19, especially if started earlier in the course of
the disease, but further RCTs including a larger number of
patients are needed.
8. Conclusion
Taking into account the results of all the available
laboratory and clinical trials on the subject, monoclonal
antibodies seem to be the most effective treatments for
COVID-19 at the moment and high-titer convalescent
plasma also could be effective when administered during
the early phase of the disease. As lopinavir/ritonavir,
hydroxychloroquine, merimepodib, and umifenovir were
found to be ineffective in RCTs, they should not be used
for the treatment of COVID-19. Additional clinical trials
are needed to define the role of remdesivir, favipiravir,
interferons, ivermectin, dutasteride, proxulutamide,
fluvoxamine, bromhexine, nitazoxanide, and niclosamid
in the treatment of COVID-19. Finally, the results of
phase trials are waited to learn whether or not the newer
agents such as molnupiravir, PF-07321332, PF-07304814,
plitidepsin, and AT-527 are effective in the treatment of
COVID-19.
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